Bcl2L10 also represents apredictive factor for resistance to azacitidine in myelodysplastic syndromes andacute myeloid leukemia patients [25], and for response to neoadjuvant chemoradiotherapy in locallyadvanced rectal cancer [9] orto death-inducing agents in breast cancer [12]. This evidence concerns the gene BCL2L10 and breast carcinoma.